<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325285</url>
  </required_header>
  <id_info>
    <org_study_id>10-0655</org_study_id>
    <nct_id>NCT01325285</nct_id>
  </id_info>
  <brief_title>The Response of Intraocular Pressure to Systemic Hypercapnia and Hyperoxia</brief_title>
  <official_title>The Response of Intraocular Pressure to Systemic Hypercapnia and Hyperoxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thornhill Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how intraocular pressure responds to changes in the&#xD;
      levels of carbon dioxide or oxygen that a healthy individual inspires.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In response to changes in the composition of inhaled gases, blood vessels will dilate or&#xD;
      constrict. As a result, hypercapnia or hyperoxia may affect the production and drainage of&#xD;
      aqueous humour in the anterior chamber of the eye. The balance between the production and&#xD;
      drainage of the aqueous humour determines the intraocular pressure. As this system is&#xD;
      hydrodynamic, it is expected that any increase or decrease in the production of aqueous&#xD;
      humour due to dilation or constriction of the capillaries within the ciliary body will be&#xD;
      compensated by increased or decreased drainage at the trabecular meshwork. Therefore&#xD;
      intraocular pressure is not expected to show a response to hypercapnia or hyperoxia, but this&#xD;
      supposition needs to be tested in a stably controlled manner of inducing inhaled gas&#xD;
      provocations. This study will measure the intraocular pressure at varying levels of&#xD;
      hypercapnia and hyperoxia using a sequential rebreathing circuit and automated gas blender.&#xD;
      This will allow the precise targeting and stable control of end-tidal partial pressure values&#xD;
      of carbon dioxide and oxygen.&#xD;
&#xD;
      In this study, intraocular pressure will be measured at seven different inhaled gas stages.&#xD;
      The seven stages are as follows:&#xD;
&#xD;
        1. Baseline, measured in eye A (PETCO2=38mmHg and PETO2=100mmHg)&#xD;
&#xD;
        2. 10% hypercapnic increase, measured in eye A (PETCO2=42mmHg and PETO2=100mmHg)&#xD;
&#xD;
        3. 20% hypercapnic increase, measured in eye A (PETCO2=46mmHg and PETO2=100mmHg)&#xD;
&#xD;
        4. Baseline, measured in both eyes (PETCO2=38mmHg and PETO2=100mmHg)&#xD;
&#xD;
        5. 250% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=250mmHg)&#xD;
&#xD;
        6. 500% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=500mmHg)&#xD;
&#xD;
        7. Baseline, measured in eye B (PETCO2=38mmHg and PETO2=100mmHg)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Intraocular pressure will be measured during the study visit, ten minutes into each of the seven inhaled gas provocation stages</time_frame>
    <description>Intraocular pressure will be measured using Goldmann applanation tonometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal blood flow</measure>
    <time_frame>Retinal blood flow will be measured during the second (optional) study visit, ten minutes into each of the seven inhaled gas provocation stages</time_frame>
    <description>Retinal blood flow will be measured using the Canon Laser Blood Flowmeter in a subset of participants asked to return for a second visit. This will demonstrate that retinal blood flow behaves as the study claims that it does.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Intraocular Pressure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RespirAct</intervention_name>
    <description>Participants will breathe through a mask connected to a sequential rebreathing circuit and gas blender. The following seven gas stages will be targeted for about 10 minutes each:&#xD;
Baseline, measured in eye A (PETCO2=38mmHg and PETO2=100mmHg)&#xD;
10% hypercapnic increase, measured in eye A (PETCO2=42mmHg and PETO2=100mmHg)&#xD;
20% hypercapnic increase, measured in eye A (PETCO2=46mmHg and PETO2=100mmHg)&#xD;
Baseline, measured in both eyes (PETCO2=38mmHg and PETO2=100mmHg)&#xD;
250% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=250mmHg)&#xD;
500% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=500mmHg)&#xD;
Baseline, measured in eye B (PETCO2=38mmHg and PETO2=100mmHg)</description>
    <other_name>Inhaled gas provocations</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy young individuals (age 18-30)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range 18-30 years old&#xD;
&#xD;
          -  Visual acuity of 20/20 or better&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refractive error &gt;±6.00 DS and/or ± 2.00 DC&#xD;
&#xD;
          -  History or presence of ocular disease&#xD;
&#xD;
          -  Family history of diabetes or glaucoma&#xD;
&#xD;
          -  History of intraocular or refractive surgery&#xD;
&#xD;
          -  Nursing or pregnant women&#xD;
&#xD;
          -  History of clinically diagnosed endocrine disease&#xD;
&#xD;
          -  History of vascular disease, cardiovascular disease, or any treated respiratory&#xD;
             disorders (seasonal asthma excluded from this so long as subject not taking Rx at the&#xD;
             time)&#xD;
&#xD;
          -  History of systemic hypertension&#xD;
&#xD;
          -  Habitual smoking&#xD;
&#xD;
          -  Use of medications that affect blood flow&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Hudson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alanna Adleman, BSc</last_name>
    <phone>416-603-5694</phone>
    <email>aadleman@uhnresearch.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tien Wong, BSc</last_name>
    <phone>416-603-5694</phone>
    <email>twong@uhnresearch.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Alanna Adleman, BSc</last_name>
      <phone>416-603-5694</phone>
      <email>aadleman@uhnresearch.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tien Wong, BSc</last_name>
      <phone>416-603-5694</phone>
      <email>twong@uhnresearch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Hudson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Fisher, FRCPC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Cheng, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Hosking SL, Harris A, Chung HS, Jonescu-Cuypers CP, Kagemann L, Roff Hilton EJ, Garzozi H. Ocular haemodynamic responses to induced hypercapnia and hyperoxia in glaucoma. Br J Ophthalmol. 2004 Mar;88(3):406-11.</citation>
    <PMID>14977778</PMID>
  </reference>
  <reference>
    <citation>Slessarev M, Han J, Mardimae A, Prisman E, Preiss D, Volgyesi G, Ansel C, Duffin J, Fisher JA. Prospective targeting and control of end-tidal CO2 and O2 concentrations. J Physiol. 2007 Jun 15;581(Pt 3):1207-19. Epub 2007 Apr 19.</citation>
    <PMID>17446225</PMID>
  </reference>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>February 15, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>August 17, 2011</last_update_submitted>
  <last_update_submitted_qc>August 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Christopher Hudson</name_title>
    <organization>University of Toronto, University of Waterloo, and Toronto Western Research Institute</organization>
  </responsible_party>
  <keyword>Intraocular pressure</keyword>
  <keyword>Hypercapnia</keyword>
  <keyword>Hyperoxia</keyword>
  <keyword>Rebreathing circuit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercapnia</mesh_term>
    <mesh_term>Hyperoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

